
MEDNAX (MD) Stock Forecast & Price Target
MEDNAX (MD) Analyst Ratings
Bulls say
Pediatrix Medical Group has demonstrated robust financial performance with a 6.2% same-store growth in the first quarter of 2025, indicating strong momentum driven by pricing strength. The company anticipates margin upside and improved cash flow as a result of portfolio restructuring and a transition in revenue cycle management. Additionally, adjusted earnings per share estimates for 2025 and 2026 have been raised to $1.72 and $1.84, respectively, reflecting an optimistic outlook for the company's financial trajectory.
Bears say
Pediatrix Medical Group's stock is viewed negatively due to its heavy reliance on a declining birth rate in the U.S., which poses ongoing headwinds for revenue generation. The neonatal business is characterized by limited organic growth and potential challenges in achieving consistent margins, which raises concerns about sustainability. Additionally, internal complications arising from the compensation structure may hinder recruitment and growth, while external factors such as regulatory changes and reimbursement rate shifts could further adversely impact the company's financial performance.
This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.
MEDNAX (MD) Analyst Forecast & Price Prediction
Start investing in MEDNAX (MD)
Order type
Buy in
Order amount
Est. shares
0 shares